| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 43,980 | 44,085 | 18:24 | |
| 43,985 | 44,090 | 18:24 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 650,00 | 4 | |||
| 170,00 | 8 | |||
| 135,00 | 57 | |||
| 60,00 | 15 | |||
| 52,20 | 500 | |||
| 51,76 | 50 | |||
| 45,000 | 20 | |||
| 44,375 | 189 | |||
| 44,370 | 203 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 203 | 44,250 | |||
| 189 | 44,230 | |||
| 203 | 44,225 | |||
| 100 | 41,000 | |||
| 37 | 36,000 | |||
| 120 | 20,800 | |||
| 1.052 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.904 | 0,549 | 1.046 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:56 | 43,805 | 5 |
| 17:21:12 | 43,755 | 70 |
| 17:21:08 | 43,700 | 103 |
| 17:21:08 | 43,700 | 75 |
| 17:21:08 | 43,700 | 38 |
| 17:21:08 | 43,700 | 40 |
| 17:21:08 | 43,675 | 41 |
| 17:20:59 | 43,695 | 32 |
| 17:20:59 | 43,695 | 2 |
| 17:20:59 | 43,695 | 58 |
| 17:15:04 | 43,575 | 75 |
| 17:08:56 | 43,655 | 40 |
| 17:08:52 | 43,590 | 134 |
| 17:04:34 | 43,640 | 4 |
| 15:54:12 | 43,675 | 40 |
| 15:52:47 | 43,685 | 75 |
| 15:45:21 | 44,145 | 40 |
| 15:45:13 | 44,040 | 160 |
| 15:40:56 | 44,310 | 15 |
| 15:40:09 | 44,360 | 122 |
| Tagesumsatz Xetra | -0,450 -1,02 % | 2.897 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Mi | Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? | 26 | Barchart.com | ||
| Di | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | 634 | ACCESS Newswire | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| Fr | Top Moderna Shareholders | 22 | Investopedia | ||
| 30.03. | Moderna vor entscheidender Bewährungsprobe | 756 | LYNX Broker | Moderna steht derzeit wieder stärker im Fokus technischer Beobachter. Im Chartbild zeigen sich Hinweise auf eine Stabilisierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| 27.03. | ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? | 51 | Zacks |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:33 | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS Group (DE) | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| 12:06 | Zymeworks Inc.: Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth | GlobeNewswire (Europe) | • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq:... ► Artikel lesen | |
| 13:02 | Zeo ScientifiX, Inc.: Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | ACCESS Newswire | Regen Therapy's 24,000-practitioner network will unlock a fully integrated care ecosystem - featuring Stealth Health's licensed prescriber team and specialized therapies, Metabolic Code-driven longevity... ► Artikel lesen | |
| 14:12 | C4 Therapeutics Enters Collaboration Agreement With Roche | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| 15:36 | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | AFX News | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen |